Purification process for fragment antibodies

1. A process of purifying a fragment antibody selected from the group consisting of a bispecific ScFv, ScFV fragment, Fab fragment, Fab 2 , Fab 3 , minibody, diabody, triabody, single-domain antibody, tetrabody, and multivalent antibody fragment derived tandem antibody fragment from a culture medium comprising at least one impurity comprising:

separating the fragment antibody from the culture medium, wherein

the culture medium is prepared by expression of an expression cassette encoding the fragment antibody in a recombinant prokaryotic host cell and subsequent lysis or disruption of the host cell,

the separation is carried out after reducing the pH of the culture medium to a pH at which the fragment antibody is soluble, but one or more of the impurities are insoluble, and

if a chromatographic method is performed, said reducing the pH of the culture medium is performed prior to the chromatographic method.

2. A process of purifying a fragment antibody selected from the group consisting of a bispecific ScFv, ScFV fragment, Fab fragment, Fab 2 , Fab 3 , minibody, diabody, triabody, single-domain antibody, tetrabody, and multivalent antibody fragment derived tandem antibody fragment comprising:

a) preparing a culture medium comprising a fragment antibody and at least one impurity by expression of an expression cassette encoding the fragment antibody in a recombinant prokaryotic host cell and subsequent lysis or disruption of the host cell; and

b) purifying the fragment antibody from the culture medium, wherein the purification is carried out after reducing the pH of the culture medium a pH at which the fragment antibody is soluble, but one or more of the impurities are insoluble,

wherein if a chromatographic method is performed, said reducing the pH of the culture medium is performed prior to the chromatographic method.

3. A process of separating an impurity from a culture medium comprising a fragment antibody selected from the group consisting of a bispecific ScFv, ScFV fragment, Fab fragment, Fab 2 , Fab 3 , minibody, diabody, triabody, single-domain antibody, tetrabody, and multivalent antibody fragment derived tandem antibody fragment and at least one impurity prepared by expression an expression cassette encoding the fragment antibody in a recombinant prokaryotic host cell and subsequent lysis or disruption of the host cell, which comprises

reducing the pH of the culture medium to a pH at which the fragment antibody is soluble, but one or more of the impurities are insoluble, wherein if a chromatographic method is performed, said reducing the pH of the culture medium is performed prior to the chromatographic method, and

separating the insoluble impurity from the culture medium.

4. The process according to any one of claims 1 to 3 , wherein the pH of the culture medium is from 6 to 8.

5. The process according to claim 4 , wherein the pH of the culture medium is from 6.7 to 7.5.

6. The process according to any one of claims 1 to 3 , wherein the pH of the culture medium is reduced to a pH less than 6.0.

7. The process according to claim 6 , wherein the pH of the culture medium is reduced to a pH in the range of from 3 to 5.

8. The process according to any one of claims 1 to 3 , wherein the reduction in pH is accompanied by a reduction in the ionic strength of the culture medium.

9. The process according to claim 8 , wherein the ionic strength is reduced to a conductivity of 5 mScm −1 or less.

10. The process according to any one of claims 1 to 3 , wherein the fragment antibody is subsequently purified by a purification process comprising ion exchange chromatography, hydrophobic interaction chromatography, reverse phase chromatography, hydrophobic charge induction chromatography, mixed mode chromatography, size exclusion chromatography and gel filtration or affinity chromatography.

11. The process according to claim 10 , wherein the purification process comprises cation exchange chromatography.

12. The process according to any one of claims 1 to 3 , wherein the fragment antibody is an Fab fragment; an ScFv fragment or a single domain antibody.

13. The process according to any one of claims 1 to 3 , wherein the host cell is E coli.

14. The process according to claim 13 , wherein the E coli is a B or K12 strains thereof.

15. The process according to any one of claims 1 to 3 , wherein the pH of the culture medium is from 6 to 8 and is reduced to a pH less than 6, accompanied by a reduction in the ionic strength of the culture medium.

16. The process according to claim 15 , wherein the pH of the culture medium is from 6.7 to 7.5 and is reduced to a pH in the range of from 3 to 5, accompanied by a reduction in the ionic strength of the culture medium to a conductivity of 5 mScm −1 or less.

17. The process according to claim 16 , wherein the fragment antibody is an Fab fragment; an ScFv fragment or a single domain antibody.

18. The process according to claim 1 , wherein the reducing the pH is accompanied by a reduction in the ionic strength of the culture medium.

19. A process of producing a purified fragment antibody selected from the group consisting of a bispecific ScFv, ScFV fragment, Fab fragment, Fab 2 , Fab 3 , minibody, diabody, triabody, singe-domain antibody, tetrabody, and multivalent antibody fragment derived tandem antibody fragment comprising:

culturing a recombinant prokaryotic host cell containing an expression cassette encoding the fragment antibody under conditions sufficient to produce the fragment antibody,

lysing or disrupting the prokaryotic host cell,

reducing the pH of the culture medium to a pH at which the fragment antibody is soluble, but one or more impurities are insoluble, and

separating the fragment antibody from the culture medium, wherein if a chromatographic method is performed, said reducing and separating are performed prior to the chromatographic method.

20. The process according to claim 19 , wherein the reducing comprises dialysing the culture medium against a buffer at a lower pH than the pH of the culture medium.